Choose your molecule
GLP-1 Medications Compared: Tirzepatide, Semaglutide, and What's Next
Two approved molecules, one head-to-head answer, four brand products, a new pill, and a pipeline — the medication layer of the decision, before any provider enters it.
The decision in one paragraph
Tirzepatide (Zepbound/Mounjaro) is the efficacy leader — 20.2% vs 13.7% average loss against semaglutide head-to-head — at a $70–$100/mo market premium. Semaglutide (Wegovy/Ozempic) is the evidence leader — the SELECT cardiovascular indication, the two-year durability data, the only pill — and the budget molecule. The full argument: tirzepatide vs. semaglutide; the switch path: switching guide.
Go deeper by molecule
Tirzepatide hub · Semaglutide hub · Oral GLP-1s · Compounded GLP-1s · Foundayo: the approved no-rules pill · Retatrutide phase 3 results · The 2026–2028 pipeline
Price the molecule, then the provider
Molecule choice sets your budget band before any program does: verified compounded floors are $215 (tirzepatide) and $133 (semaglutide); brand maintenance rates are $449 and $349. Then the provider layer — rankings, database, head-to-heads — decides what you pay inside the band.